Diffusion-weighted MRI predicts the histologic response for neoadjuvant therapy in patients with pancreatic cancer: a prospective study (DIFFERENT trial).
Ken-Ichi OkadaManabu KawaiSeiko HironoFumiyoshi KojimaKensuke TaniokaMasaki TeradaMotoki MiyazawaYuji KitahataYoshifumi IwahashiMasaki UenoShinya HayamiShin-Ichi MurataToshio ShimokawaHiroki YamauePublished in: Langenbeck's archives of surgery (2020)
Post-treatment whole-tumor ADC value may be a predictor of R0 resectability in patients with BRPC. Tumor cell destruction rate is indicated by the difference between pre-/post-treatment ADC values. This difference is strongly affected by the pre-treatment ADC value. The cutoff value of ADC at the site of vascular contact could not discriminate R0 resectability.